Study yields more than a million new cyclic compounds, some with pharmaceutical potential

Researchers say they can now produce a vast library of unique cyclic compounds, some with the capacity to interrupt specific protein-protein interactions that play a role in disease. The new compounds have cyclic structures that give them stability and enhance their ability to bind to their targets.

The study, reported in the journal Nature Chemical Biology, also revealed that one of the newly generated compounds interferes with the binding of an HIV protein to a human protein, an interaction vital to the virus's life cycle.

Most drug-discovery efforts focus on disease-inducing interactions in enzymes and proteins that involve classic "lock-and-key" mechanisms, said University of Illinois chemistry professor Wilfred van der Donk, a Howard Hughes Medical Institute Investigator who co-led the study with University of Southampton chemical biology professor Ali Tavassoli. "In most cases, small chemical drugs bind to cavities in enzymes, where the chemical reactions take place. By binding to these crevices, the drugs prevent the enzymes from working."

However, many disease processes involve protein-protein interactions that do not fit this model, van der Donk said.

"These have long been considered challenging because they do not involve such cavities. These protein-protein interactions often are made up of extended surfaces that can be difficult to inhibit with small molecules," he said.

Linear peptides also are problematic. They can be "floppy, like spaghetti, and therefore most of the time are in incorrect orientations to bind," van der Donk said. Cyclic molecules composed of one or more rings of amino acids are more stable and less susceptible to cellular enzymes that tend to chew off the ends of linear peptides. They are thus more likely to successfully bind to their targets.

In the new study, van der Donk and his colleagues made use of an enzyme they discovered from a bacterium that lives in the ocean.

"This enzyme's natural role is to make about 30 different cyclic proteins, and we tested whether it could make analogs of these natural products in Escherichia coli," van der Donk said. E. coli has been used as a drug-producing factory for pharmaceutical products.

The genetic sequences inserted into E. coli all coded for a series of amino acids recognized by the enzyme. By randomly adding specific amino acids to this "leader sequence," the team was able to generate a library of more than a million unique multicyclic proteins.

Tavassoli and his colleagues next screened this library in genetically engineered E. coli for proteins that could interrupt the binding of the HIV protein to its human host cell target.

"We engineered the genes of the E. coli strain such that its survival depended on disrupting the interaction between the human protein and an HIV protein," Tavassoli said. His team found three potential therapeutic agents. Further testing revealed that one of the three worked best. In a test tube and in cells, the compound bound to the human protein, stopping the HIV protein from interacting with it.

This drug agent likely will not be used therapeutically, however, as it may have toxic side effects at high doses as a result of its interaction with the human protein, the researchers said.

"The real advance here is the ability to generate libraries of millions of potentially therapeutic agents," Tavassoli said. "These could be screened to identify inhibitors of other disease-related processes, which is where its real potential lies."

Xiao Yang, Katherine R Lennard, Chang He, Mark C Walker, Andrew T Ball, Cyrielle Doigneaux, Ali Tavassoli, Wilfred A van der Donk.
A lanthipeptide library used to identify a protein–protein interaction inhibitor.
Nature Chemical Biology (2018). doi: 10.1038/s41589-018-0008-5.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...